Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: A case report

被引：4

作者：

Ueda K. ^{[1
]}

Suekane S. ^{[1
]}

Ogasawara N. ^{[1
]}

Chikui K. ^{[1
]}

Suyama S. ^{[1
]}

Nakiri M. ^{[1
]}

Nishihara K. ^{[1
]}

Matsuo M. ^{[1
]}

Igawa T. ^{[1
]}

机构：

[1] Department of Urology, Kurume University School of Medicine, 67 Asahi-machi, Kurume

来源：

Journal of Medical Case Reports | / 10卷 / 1期

关键词：

Long-term response; Monotherapy; Renal cell carcinoma; Sorafenib;

D O I：

10.1186/s13256-016-0961-0

中图分类号：

学科分类号：

摘要：

Background: Molecular targeted therapies have dramatically improved the prognosis of metastatic renal cell carcinoma. However, patients in whom the treatment could initially be effective will experience disease progression later. Case presentation: A 74-year-old Japanese man who was diagnosed with renal cell carcinoma with no evidence of metastasis presented to our hospital. He initially underwent radical nephrectomy, and subsequently the disease metastasized to the lung. Sorafenib was started for the lung metastases 1 year after the operation. The dose of sorafenib was reduced and temporarily discontinued because adverse events, including fatigue and cardiac infarction, occurred. The patient has continued sorafenib monotherapy for over 10 years without disease progression and severe adverse events. Conclusions: We present a rare case of a patient with metastatic renal cell carcinoma who has survived for over 10 years while receiving sorafenib monotherapy. © 2016 The Author(s).

引用

共 25 条

[11]

Ueda K., Suekane S., Nishihara K., Ogasawara N., Kurose H., Hayashi S., Et al., Duration of first-line treatment with molecular targeted-therapy is a prognostic factor in metastatic renal cell carcinoma, Anticancer Res, 35, pp. 3415-3421, (2015)

[12]

Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., Et al., Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, pp. 2505-2512, (2006)

[13]

Rini B.I., Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma, Cancer, 115, pp. 2306-2312, (2009)

[14]

Akaza H., Tsukamoto T., Murai M., Nakajima K., Naito S., Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma, Jpn J Clin Oncol, 37, pp. 755-762, (2007)

[15]

Tanigawa G., Kawashima A., Yamaguchi S., Nishimura K., Miyoshi S., Kajikawa J., Et al., Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice, Jpn J Clin Oncol, 41, pp. 1265-1270, (2011)

[16]

Kusuda Y., Miyake H., Behnsawy H.M., Fukuhara T., Inoue T.A., Fujisawa M., Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens, Urol Oncol, 31, pp. 42-50, (2013)

[17]

Jonasch E., Corn P., Pagliaro L.C., Warneke C.L., Johnson M.M., Tamboli P., Et al., Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: Clinical and biomarker analysis, Cancer, 116, pp. 57-65, (2010)

[18]

Aziz S.A., Sznol J.A., Albiges L., Zito C., Jilaveanu L.B., Camp R.L., Et al., Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma, Cancer Cell Int, 14, (2014)

[19]

Stadler W.M., Figlin R.A., McDermott D.F., Dutcher J.P., Knox J.J., Miller W.H., Et al., Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America, Cancer, 116, pp. 1272-1280, (2010)

[20]

Schmidinger M., Zielinski C.C., Vogl U.M., Bojic A., Bojic M., Schukro C., Et al., Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma, J Clin Oncol, 26, pp. 5204-5212, (2008)

← 1 2 3 →